Table 4.
Demographics of the patients successfully genotyped by mutation status*
| EGFR † | KRAS † | ALK | BRAF | HER2 | pik3ca † | Wild-type | |
|---|---|---|---|---|---|---|---|
| Proportion mutated (%) | 55‡/334 (16) | 79/325 (24) | 16/309 (5) | 16/341 (5) | 15/341 (4) | 6/341 (2) | 128/313 (41) |
| Median age (range) | 58 (34-81) | 63 (30-82) | 54 (24-79) | 61 (41-77) | 61 (44-75) | 66 (30-81) | 63 (26-87) |
| Gender -- no. (%) | |||||||
| Male | 21 (38) | 28 (35) | 4 (25) | 7 (44) | 6 (40) | 3 (50) | 68 (53) |
| Female | 34 (62) | 51 (65) | 12 (75) | 9 (56) | 9 (60) | 3 (50) | 60 (47) |
| Race -- no. (%) | |||||||
| White, non-Hispanic | 51 (93) | 74 (94) | 15 (94) | 15 (94) | 14 (93) | 5 (83) | 107 (84) |
| White, Hispanic | 0 | 1 (1) | 1 (6) | 0 | 0 | 0 | 4 (3) |
| Asian | 1 (2) | 1 (1) | 0 | 0 | 1 (7) | 0 | 6 (5) |
| Black | 3 (5) | 2 (3) | 0 | 1 (6) | 0 | 1 (17) | 10 (8) |
| Other | 0 | 1 (1) | 0 | 0 | 0 | 0 | 1 (1) |
| Smoking Status -- no. (%)§ | |||||||
| Never-smoker | 29 (53) | 5 (6) | 6 (38) | 5 (31) | 10 (67) | 4 (67) | 24 (19) |
| ≤ 10 pack-years | 12 (22) | 3 (4) | 6 (38) | 3 (19) | 4 (27) | 0 | 8 (6) |
| ≥ 10 pack-years | 14 (25) | 71 (90) | 4 (25) | 8 (50) | 1 (7) | 2 (33) | 93 (73) |
| Histology -- no. (%) | |||||||
| Adenocarcinoma | 53 (96) | 73 (92) | 14 (88) | 12 (75) | 13 (87) | 4 (67) | 107 (84) |
| Adenosquamous | 2 (4) | 3 (4) | 0 | 1 (6) | 1 (7) | 1 (17) | 5 (4) |
| Squamous | 0 | 0 | 0 | 0 | 0 | 0 | 3 (2) |
| Large cell carcinoma | 0 | 0 | 1 (6) | 0 | 0 | 0 | 1 (1) |
| NSCLC NOS | 0 | 3 (4) | 1 (6) | 3 (19) | 1 (7) | 1 (17) | 12 (9) |
*
Three patients with two separate tumor specimens successfully genotyped were accounted for only once in the respective genotype cohort.
†
Three patients had tumors bearing concurrent mutations in PIK3CA and either KRAS (n=2) or EGFR (n=1); the demographics of the patient corresponding with each of the 3 tumor specimens were included and accounted for in the respective genotype cohort.
‡
One patient had samples from two different body sites tested, both of which showed an exon 20 insertion mutation of EGFR. The demographics of the patient were accounted for only once in the EGFR cohort.
§
Data not available for 3 patients in the wild-type cohort.